AstraZeneca (AZN) reported Q3 FY 2021 earnings of $1.08 per share (versus $0.94 per share in Q3 FY 2020), missing analysts’ consensus estimate of $1.25 per share.
The company’s quarterly revenues amounted to $9.741 bln (+48.1% y/y), beating analysts’ consensus estimate of $9.580 bln.
The company also reaffirmed guidance for FY 2021, projecting EPS of $5.05-5.40 versus analysts’ consensus estimate of $5.27.
AZN fell to $60.92 (-3.18%) in pre-market trading.
